Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives

Haematologica

Volumn 85, Issue 12, 2000, Pages 1271-1276

  Aznar, J ^a   Vaya A ^a   Estelles A ^a   Mira, Y ^a   Segui R ^a   Villa, P ^a   Ferrando, F ^a   Falco C ^a   Corella, D ^a   Espana F ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Acquired thrombophilic risk factors; Factor V Leiden; Oral contraceptives; Prothrombin G20210A; Thrombosis

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; HEPARIN COFACTOR II; ORAL CONTRACEPTIVE AGENT; PLASMINOGEN; PROTEIN C; PROTEIN S; PROTHROMBIN;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; EUROPE; FAMILY HISTORY; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PREVALENCE; RISK FACTOR; THROMBOPHILIA; VEIN THROMBOSIS;

ADULT; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; DRUG INTERACTIONS; FACTOR V; FEMALE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; POINT MUTATION; PROTHROMBIN; RISK FACTORS; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 0034511765     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Factor V Leiden and other coagulation factor mutations affecting thrombotic risk
2. A common genetic variant in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and increase in venous thrombosis
3. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis
4. The prothrombin gene G20210A variant: Prevalence in a U.K. anticoagulant clinic population
5. Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease
6. Risk of venous thromboembolism associated with a G to A transition at position 20210 in the 3′ -untranslated region of the prothrombin gene
7. The venous thrombosis risk factor 20210 A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease
8. The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease
9. A prothrombin gene mutation is significantly associated with venous thrombosis
10. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia
11. Lack of association between thrombosis in primary antiphospholipid syndrome and the recently described thrombophilic 3′ -untranslated prothrombin gene polymorphism
12. The A20210 allele of the prothrombin gene is not frequently associated with the factor V Arg 506 to Gln mutation in thrombophilic families
13. Prevalence of 20210 A allele of the prothrombin gene in venous thromboembolism patients
14. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients
15. Risk of stroke in young women and two prothrombotic mutations: Factor V Leiden and prothrombin gene variant
16. Increased risk for venous thrombosis in carriers of the prothrombin G→A20210 gene variant
17. Prevalence of FVR506Q and prothrombin 20210A mutations in the Navarrese population
18. The prothrombin 20210A allele is the most prevalent genetic risk factor for venous thromboembolism in the spanish population
19. Geographic distribution of the 20210 G to A prothrombin variant
20. The prothrombin 20210A allele is frequently coinherited in young carriers of the factor V Arg 506 to Gln mutation with venous thrombophilia
21. The prothrombin gene 3′-untranslated region mutation is frequently associated with factor V Leiden in thrombophilic patients and shows ethnic-specific variation in allele frequency
22. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: Prevalence and risk assessment
23. Coexistence of factor V Leiden and Factor II A20210 mutations and recurrent venous thromboembolism
24. Validated questionnaire for the identification of previous personal or familial venous thromboembolism
25. Modified test for activate protein C resistance
26. A rapid screening method for the factor V Arg 506 Gln mutation
27. Activation of heparin cofactor II by dermatan sulphate
28. Determination of functional and antigen protein C inhibitor and its complexes with activated protein C in plasma by ELISA's
29. The 20210A allele of prothrombin is not found among sickle cell disease patients from west Africa
30. Thrombophilia as a multigenic disease
31. Epidemiology of factor V Leiden: Clinical implications
32. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation
33. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation
34. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis